19 September 2019  
EMA/CHMP/506821/2019  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Dupixent 
Dupilumab 
On 19 September 2019, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a change to the terms of the marketing authorisation for the medicinal product 
Dupixent. The marketing authorisation holder for this medicinal product is Sanofi-Aventis Groupe. 
The CHMP adopted a new indication as follows: 
“Chronic rhinosinusitis with nasal polyposis (CRSwNP) 
Dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults 
with severe CRSwNP for whom therapy with systemic corticosteroids and/or surgery do not provide 
adequate disease control.” 
For information, the full indications for Dupixent will be as follows:2 
“Atopic Dermatitis 
Dupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and 
adolescents 12 years and older who are candidates for systemic therapy. 
Asthma 
Dupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment 
for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised 
FeNO (see section 5.1), who are inadequately controlled with high dose ICS plus another medicinal 
product for maintenance treatment. 
Chronic rhinosinusitis with nasal polyposis (CRSwNP) 
Dupixent is indicated as an add-on therapy with intranasal corticosteroids for the 
treatment of adults with severe CRSwNP for whom therapy with systemic corticosteroids 
and/or surgery do not provide adequate disease control.” 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 days 
from adoption of the opinion 
2 New text in bold 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union   
© European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged. 
 
  
 
 
 
  
                                                
Detailed recommendations for the use of this product will be described in the updated summary of product 
characteristics (SmPC), which will be published in the revised European public assessment report (EPAR), 
and will be available in all official European Union languages after a decision on this change to the marketing 
authorisation has been granted by the European Commission. 
Dupixent  
EMA/CHMP/506821/2019 
Page 2/2 
 
 
 
  
  
